GILEAD SCIENCES LTD (WT) - WT2022-12 - AMPHOTERICIN LIPOSOMAL (AMBISOME) 50 mg Powder for reconstitution INF;1 Vial Pack - 3 YEARS
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Region | Northern Ireland |
| Procedure | limited |
| OCID | ocds-h6vhtk-03a59c |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| GILEAD SCIENCES INTERNATIONAL LTD. | · | · | active |
description
Supply of AMPHOTERICIN LIPOSOMAL (AMBISOME) 50 mg Powder for reconstitution INF;1 Vial Pack to meet clinical need in the Western Trust for 3 YEARS
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 14 Feb 2023 | Contract award notice (F03) | Earlier regulations | 004542-2023 |
more from Western Health and Social Care Trust
- Provision of Domiciliary Care Services in the Western Health and Social Care Trust Area · 19 Dec 2025
- Provision of Domiciliary Care Services in the Western Health and Social Care Trust Area · 19 Dec 2025
- Provision of Domiciliary Care Services in the Western Health and Social Care Trust Area · 19 Dec 2025
- Provision of Domiciliary Care Services in the Wester Health & Social Care Trust · 19 Dec 2025
- Provision of Domiciliary Care Services in the Western Health and Social Care Trust Area · 19 Dec 2025
- Bristol Myers Squibb - WT2024-28 - POMALIDOMIDE (1mg, 2 mg, 3mg, 4mg) Capsules · 10 Oct 2024
- WHSCT 4833652 - Construction of a New Health and Care Centre in Lisnaskea · £20,000,000 · 27 Sept 2024
- NOVARTIS PHARMACEUTICALS UK LTD (WT) - WT2024-11, WT2024-12, WT2024-13 - RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets, SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300 mg in 2mLInjections · 23 Aug 2024
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.